Priority Review Vouchers: Does Novartis Have User's Regret?
This article was originally published in The Pink Sheet Daily
Executive Summary
Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.